Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | TTK | P33981 | 1/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.46 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 10/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HTR1D | P28221 | 1/20 | 0.32 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15574103 | 0.82 | AURKA (0.45) | AURKATTKAURKBINCENPALDH1A1 | |
| SCHEMBL24565779 | 0.79 | AURKA (0.42) | AURKATTKAURKBINCENPBRD4 | |
| SCHEMBL12157418 | 0.79 | BRD4 (0.48) | BRD4POLB | |
| SCHEMBL23957950 | 0.78 | MEN1 (0.37) | AURKATTKAURKBINCENPMEN1 | |
| SCHEMBL13688726 | 0.78 | GABBR2 (0.32) | ALDH1A1MAPTBRD4 | |
| SCHEMBL22213805 | 0.76 | CREBBP (0.35) | BRD4HTR1D | |
| SCHEMBL19871785 | 0.76 | BRD4 (0.31) | BRD4 | |
| SCHEMBL23351070 | 0.74 | HTR1D (0.34) | BRD4HTR1D | |
| SCHEMBL4049110 | 0.74 | BRD4 (0.39) | MEN1KMT2ABRD4 | |
| SCHEMBL28223511 | 0.74 | AURKA (0.52) | AURKATTKAURKBINCENPALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1867646-A1 | Cytokine inhibitors | Boehringer Ingelheim Pharmaceuticals, Inc. (US) | 2007-12-19 | — | — | EP | claimed |
| US-7285545-B2 | N-Pyridyl-7-substituted-2-indolecarboxamides, e.g., 1-Methyl-7-[2-(4-methyl-piperazin-1-yl)-pyrimidin-4-yloxy]-1H-indole-2-carboxylic acid (2-tert-butyl-5-methoxy-pyridin-4-yl)-amide; used to treat chronic inflammatory diseases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-10-23 | — | — | US | claimed |
| EP-1745036-A2 | CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2007-01-24 | — | — | EP | claimed |
| WO-2005108387-A2 | CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-11-17 | — | — | WO | claimed |
| US-20050245536-A1 | Cytokine inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-11-03 | — | — | US | claimed |
| US-10570118-B2 | Isoquinolones as BTK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-02-25 | — | — | US | disclosed |
| US-20190023686-A1 | ISOQUINOLONES AS BTK INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-01-24 | — | — | US | disclosed |
| US-7592332-B2 | Cytokine inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-09-22 | — | — | US | disclosed |
| US-7592332-B2 | Cytokine inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-09-22 | — | — | US | disclosed |
| US-7592332-B2 | Cytokine inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-09-22 | — | — | US | disclosed |
| US-20090023701-A1 | Cytokine Inhibitors | AUNGST RONALD A | 2009-01-22 | — | — | US | disclosed |
| US-20090023701-A1 | Cytokine Inhibitors | AUNGST RONALD A | 2009-01-22 | — | — | US | disclosed |
| US-20070275946-A1 | Cytokine Inhibitors | AUNGST RONALD A | 2007-11-29 | — | — | US | disclosed |
| US-20070275946-A1 | Cytokine Inhibitors | AUNGST RONALD A | 2007-11-29 | — | — | US | disclosed |
| US-7285545-B2 | N-Pyridyl-7-substituted-2-indolecarboxamides, e.g., 1-Methyl-7-[2-(4-methyl-piperazin-1-yl)-pyrimidin-4-yloxy]-1H-indole-2-carboxylic acid (2-tert-butyl-5-methoxy-pyridin-4-yl)-amide; used to treat chronic inflammatory diseases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-10-23 | — | — | US | disclosed |
| US-7285545-B2 | N-Pyridyl-7-substituted-2-indolecarboxamides, e.g., 1-Methyl-7-[2-(4-methyl-piperazin-1-yl)-pyrimidin-4-yloxy]-1H-indole-2-carboxylic acid (2-tert-butyl-5-methoxy-pyridin-4-yl)-amide; used to treat chronic inflammatory diseases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-10-23 | — | — | US | disclosed |
| US-7285545-B2 | N-Pyridyl-7-substituted-2-indolecarboxamides, e.g., 1-Methyl-7-[2-(4-methyl-piperazin-1-yl)-pyrimidin-4-yloxy]-1H-indole-2-carboxylic acid (2-tert-butyl-5-methoxy-pyridin-4-yl)-amide; used to treat chronic inflammatory diseases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-10-23 | — | — | US | disclosed |
| EP-1745036-A2 | CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2007-01-24 | — | — | EP | disclosed |
| WO-2005108387-A2 | CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-11-17 | — | — | WO | disclosed |
| US-20050245536-A1 | Cytokine inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023701-A1 | Cytokine Inhibitors | IL1B, TNF, IL1A | AURKA 4213/4885TTK 4197/4885AURKB 2750/4885 |
| US-20050245536-A1 | Cytokine inhibitors | IL1B, TNF, IL1A | AURKA 4213/4885TTK 4197/4885AURKB 2750/4885 |
| US-20070275946-A1 | Cytokine Inhibitors | IL1B, TNF, IL1A | AURKA 4213/4885TTK 4197/4885AURKB 2750/4885 |
| US-10570118-B2 | Isoquinolones as BTK inhibitors | BTK, SYK, LYN | AURKA 804/4885TTK 687/4885AURKB 385/4885 |
| US-20190023686-A1 | ISOQUINOLONES AS BTK INHIBITORS | BTK, SYK, LYN | AURKA 804/4885TTK 687/4885AURKB 385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.